Mironova Labs · Protocol
Lipidation / Linker Attachment Protocol
Fatty diacid–spacer conjugation to lysine for long-acting peptides
Reagents
| Reagent | Role | Amount |
|---|---|---|
| Fatty diacid–spacer construct (e.g., C18 or C20 linker) | Acyl donor | 1.5–2.0 eq |
| DMTMM salt | Coupling reagent | 1.5–2.5 eq |
| NMM | Base | 3.0–5.0 eq |
| Peptide with free ε-lysine | Nucleophile | 1.0 eq |
Conditions
Solvent
DMF/water (4:1 or higher water fraction) for Cl; neat DMF or NMP for BF₄. Note: DMTMM·Cl has a half-life of ~15 min in neat DMF — use BF₄ or PF₆ if organic-phase pre-activation is required.
Temperature
0–25 °C (lower temperatures reduce over-acylation)
Reaction Time
2–8 h
Atmosphere
Ambient or N₂
Procedure
- 1
If peptide has multiple free amines, ensure orthogonal protection so that only the target ε-lysine is available for acylation.
- 2
Dissolve fatty diacid–spacer construct (1.5–2.0 eq) in DMF or DMF/water mixture at 0–10 °C.
- 3
Add DMTMM salt (1.5–2.5 eq) and NMM (3.0–5.0 eq). Stir for 5–10 min to pre-activate the carboxyl group.
- 4
Add the peptide (1.0 eq, dissolved in minimum DMF or buffer) to the activated acid solution.
- 5
Stir at 0–25 °C for 2–8 h. Monitor by analytical HPLC.
- 6
Quench by dilution with cold water or buffer. Purify by preparative HPLC.
Expected Outcome
Target: selective mono-acylation of target lysine with minimal over-acylation. These are expected outcomes based on general DMTMM coupling behavior; actual results require process-specific optimization (see notes).
Analytical Monitoring
Analytical RP-HPLC (C18, gradient). LC-MS for identity confirmation. Monitor for di-acylated species and triazine adducts.
Troubleshooting
Over-acylation (di-acylated product)
Reduce DMTMM equivalents to 1.2 eq. Lower temperature to 0 °C. Reduce reaction time. Ensure orthogonal protection of non-target amines.
Low conversion
Increase DMTMM equivalents. Extend reaction time. Ensure fatty acid is fully dissolved (add DMSO if needed for solubility).
Triazine adduct detected
Reduce DMTMM excess. This side product is typically separable by prep HPLC but is best minimized at the reaction level.
Notes
- These conditions are chemically plausible extrapolations from general DMTMM amide coupling data. DMTMM has been demonstrated to form amide bonds to lysine ε-amino groups in protein cross-linking contexts (Leitner et al., 2014 [B18]), establishing chemical competence for carboxyl→lysine amide formation. Farkaš et al. (2013 [B22]) further demonstrated DMTMM-mediated conjugation to BSA lysine residues. However, no published study has specifically demonstrated DMTMM for GLP-1 peptide lipidation at manufacturing scale. Users should treat this as an evaluation starting point.
- For semaglutide-class molecules, the lipidation step is quality-critical. Coupling-reagent choice directly affects the impurity profile.
- DMTMM mechanistically avoids the guanidinylation risk inherent to HATU/HBTU at this step.
- Batch-to-batch reagent purity (≥99%) is important for reproducible impurity profiles at scale.
References
- [B4] Kamiński ZJ, Paneth P, Rudzinski J. N-Triazinylammonium Tetrafluoroborates: A New Generation of Efficient Coupling Reagents Useful for Peptide Synthesis. J. Am. Chem. Soc. (2005). DOI
- [B7] Vrettos EI, et al.. Guanidinylation Side Reactions from Uronium/Guanidinium Peptide Coupling Reagents. RSC Advances (2017). DOI
- [B18] Leitner A, Joachimiak LA, Unverdorben P, Walzthoeni T, Frydman J, Förster F, Aebersold R. Chemical Cross-Linking/Mass Spectrometry Targeting Acidic Residues in Proteins and Protein Complexes. Proc. Natl. Acad. Sci. USA (2014). DOI
- [B22] Farkaš P, Čížová A, Bekešová S, Bystrický S. Comparison of EDC and DMTMM Efficiency in Glycoconjugate Preparation. Int. J. Biol. Macromolecules (2013)
Ready to Evaluate?
Mironova Labs manufactures DMTMM·Cl (mixed solvent) or DMTMM·BF₄ (organic phase) at ≥99% purity in Fairfield, NJ. Request evaluation material to test this protocol with your substrates.
Safety & Regulatory Notice
- • For research use only. Not intended for human or veterinary diagnostic or therapeutic use.
- • Consult the Safety Data Sheet (SDS) for each reagent before use. Follow all institutional safety protocols, including appropriate PPE, fume hood requirements, and waste disposal procedures.
- • This protocol is not validated for regulated manufacturing. Users are responsible for process validation and regulatory compliance in their jurisdiction.
- • Conditions described are starting points derived from published literature. Optimization for your specific substrates, scale, and equipment is required.